Introduction {#S1}
============

[C]{.ul}lustered, [r]{.ul}egularly [i]{.ul}nterspaced, [s]{.ul}hort [p]{.ul}alindromic [r]{.ul}epeat (CRISPR) loci and their [C]{.ul}RISPR [as]{.ul}sociated (Cas) proteins provide adaptive immunity to bacteria and archaea against their viruses^[@R1]^. To adapt to highly dynamic viral populations, CRISPR-Cas loci evolve rapidly, acquiring short phage sequences, known as spacers, that integrate between CRISPR repeats and constitute a memory record of infection^[@R2]^. Spacers are transcribed into small CRISPR RNAs (crRNAs) that identify viral targets (defined as protospacers) by direct Watson-Crick pairing with invasive DNA^[@R3]^. Based on their *cas* gene content, CRISPR-Cas systems can be classified into three distinct types, I, II and III^[@R4]^. Each CRISPR-Cas type possesses different mechanisms of crRNA biogenesis, target destruction and prevention of autoimmunity. In the type II CRISPR-Cas system present in *Streptococcus pyogenes* the Cas9 nuclease inactivates infective phages using crRNAs as guides to introduce double-strand DNA breaks into the viral genome^[@R5]^. Cas9 cleavage requires the presence of a [p]{.ul}rotospacer [a]{.ul}djacent [m]{.ul}otif (PAM) sequence immediately downstream of the protospacer^[@R6],[@R7]^. This requirement avoids the cleavage of the spacer sequence within the CRISPR array, i.e. autoimmunity, since the adjacent repeat lacks a PAM sequence. The importance of the PAM sequence for target recognition and cleavage^[@R6]--[@R9]^ suggests the presence of a mechanism to ensure that newly acquired spacer sequences match protospacers flanked by a proper PAM sequence. For the type I-E CRISPR-Cas system of *Escherichia coli*, over-expression of *cas1* and *cas2* is sufficient for the acquisition of new spacers in the absence of phage infection. Reports indicate that spacers acquired in this fashion match preferentially (25--70%, depending on the study) to protospacers with the correct PAM (AWG, W=A/T)^[@R10]--[@R13]^, suggesting that Cas1 and Cas2 are sufficient for spacer acquisition and have some intrinsic ability to recognize protospacers with the right PAM. In the type II system of *S. pyogenes* the PAM sequence is NGG (and also NAG at a much lower frequency)^[@R3],[@R6],[@R14]^, where N is any nucleotide, and it is recognized and bound by a domain within the Cas9 tracrRNA:crRNA-guided nuclease during target cleavage^[@R7],[@R15]^. How spacers are acquired in this system, particularly how spacers with correct PAM sequences are selected during this process, is not known.

Cas9 is required for spacer acquisition {#S2}
=======================================

To investigate the mechanisms of recognition of PAM-adjacent protospacers during spacer acquisition, we cloned the type II-A CRISPR-Cas locus of *S. pyogenes* ([Fig. 1a](#F1){ref-type="fig"}) into the staphylococcal vector pC194^[@R16]^ and introduced the resulting plasmid \[pWJ40 (ref.^[@R17]^)\] into *Staphylococcus aureus* RN4220^[@R18]^, a strain lacking CRISPR-Cas loci. We chose this experimental system because it facilitates the genetic manipulation of the *S. pyogenes* CRISPR-Cas system. We first tested the ability of the cells to mount adaptive CRISPR immunity by infecting them with the staphylococcal phage ϕNM4γ4, a lytic variant of ϕNM4^[@R19]^ (see Methods for a description of ϕNM4γ4 isolation). Plate-based assays performed by mixing bacteria and phage in top agar allowed the selection of phage-resistant colonies that were checked by PCR to look for the expansion of the CRISPR array ([Extended Data Fig. 1a](#F4){ref-type="fig"}). On average 50 % of the colonies acquired one or more spacers (8/13, 5/11 and 7/16 in three independent experiments), whereas the rest of the resistant colonies survived phage infection by a non-CRISPR mechanism, most likely including phage receptor mutations ([Extended Data Fig. 2a](#F5){ref-type="fig"}). To maximize the capture of new spacer sequences, we performed the same assay in liquid and recovered surviving bacteria at the end of the phage challenge. These were analyzed by PCR of the CRISPR array and the amplification products of expanded loci were subjected to Illumina MiSeq sequencing to determine the extent of spacer acquisition. Analysis of 2.96 million reads detected protospacers adjacent to 2083 out of 2687 NGG sequences present in the viral genome, although with variation in the frequency of acquisition of each sequence ([Extended Data Fig. 1b](#F4){ref-type="fig"}). The data revealed a prominent selection of spacers matching protospacers with downstream NGG PAM sequences (99.97 %, [Extended Data Fig. 1c](#F4){ref-type="fig"}). The acquisition of new spacers by cells in liquid culture proved to be simple and highly efficient, providing the possibility to look at millions of new spacers in a single step. It was therefore implemented in the rest of our studies.

To determine the genetic requirements for spacer acquisition we made individual deletions of *cas1, cas2* or *csn2* and challenged the mutant strains with phage ϕNM4γ4. Spacer acquisition was decreased to levels below our limit of detection in each of these mutants ([Fig. 1b](#F1){ref-type="fig"}), corroborating previous experiments^[@R12],[@R20]^. Therefore while Cas1, Cas2 and Csn2 are dispensable for anti-phage immunity in the presence of a pre-existing spacer ([Extended Data Fig. 2b and c](#F5){ref-type="fig"}), they are required for spacer acquisition. To determine whether these genes are also sufficient for this process, we over-expressed *cas1, cas2* and *csn2* in the absence of *cas9* using a tetracycline-inducible promoter in plasmid pRH223 and looked for the integration of new spacers in the absence of phage infection using a highly sensitive PCR assay ([Extended Data Fig. 3](#F6){ref-type="fig"}). We were unable to detect new spacers even in the presence of the inducer ([Fig. 1c](#F1){ref-type="fig"}). However, the addition of a second plasmid expressing tracrRNA (see below) and Cas9 from their native promoters (Fig. S4a) enabled spacer acquisition only in the presence of the inducer, with all the new spacers matching chromosomal or plasmid sequences ([Fig. 1c](#F1){ref-type="fig"} and [Extended Data Table 1](#T1){ref-type="table"}). Although most likely the acquisition of such spacers causes cell death or plasmid curing, respectively, the acquisition event can still be detected in liquid culture using our highly sensitive PCR assay ([Extended Data Fig. 3b and c](#F6){ref-type="fig"}). The tracRNA ([Fig. 1a](#F1){ref-type="fig"}) is a small RNA bound by Cas9 that is required for crRNA processing^[@R3]^ and Cas9 nuclease activity^[@R6]^. We wondered if Cas9 involvement in spacer acquisition also required the presence of the tracrRNA. Deletion of the tracrRNA prevented spacer acquisition in the absence of phage infection ([Fig. 1c](#F1){ref-type="fig"}), suggesting that apo-Cas9 is not sufficient to promote spacer acquisition and that association with its cofactor is also required. Altogether these data indicate that Cas1, Cas2 and Csn2 are necessary but not sufficient for the incorporation of new spacers and that tracrRNA/Cas9 is also required. This is in contrast to the type I-E CRISPR-Cas system of *E. coli*, where over-expression of Cas1 and Cas2 alone is sufficient for spacer acquisition^[@R10]--[@R13]^. It is important to note that the CRISPR array used in this assay consists of a single repeat, without pre-existing spacers ([Extended Data Fig. 3](#F6){ref-type="fig"}). Therefore the Cas9 requirement is not a consequence of the phenomenon known as "primed" spacer acquisition. This refers to an increase in the frequency of spacer acquisition observed in type I CRISPR-Cas systems that relies on the presence of a pre-existing spacer with a partial match to the phage genome as well as the full targeting complex (Cascade)^[@R12],[@R21],[@R22]^.

Cas9 specifies the PAM sequence of newly acquired spacers {#S3}
=========================================================

Given this newfound requirement in the CRISPR adaptation process and the well-established PAM recognition function of Cas9 during the surveillance and destruction of viral target sequences, we hypothesized that this nuclease could participate in the selection of PAM sequences during spacer acquisition. To test this we exchanged the *cas9* genes of *S. pyogenes* (Sp) and *S. thermophilus* (St) CRISPR-Cas systems to create two chimeric CRISPR loci: *tracrRNA*^Sp^-*cas9*^St^-*cas1*^Sp^-*cas2*^Sp^-*csn2*^Sp^ and *tracrRNA*^St^-*cas9*^Sp^-*cas1*^St^-*cas2*^St^-*csn2*^St^ ([Fig. 2a](#F2){ref-type="fig"}). We chose the type II-A CRISPR-Cas system of *S. thermophilus* (also known as CRISPR3^[@R23]^) because it is an ortholog of the *S. pyogenes* system^[@R24]^. While the PAM sequence for the Sp CRISPR-Cas system is NGG, the PAM sequence for the St system is NGGNG^[@R23]^ ([Fig. 2b](#F2){ref-type="fig"} and [Extended Data Table 1](#T1){ref-type="table"}). We infected each naïve strain with phage ϕNM4γ4, sequenced the newly acquired spacers, and obtained the PAM of the matching protospacers using WebLogo^[@R25]^. We found that each chimeric system acquired spacers with PAMs that correlated with the *cas9*, but not the *tracrRNA, cas1, cas2* or *csn2*, allele present ([Fig. 2b](#F2){ref-type="fig"} and [Extended Data Table 1](#T1){ref-type="table"}). To rule out the possibility that non-functional spacers are negatively selected during phage infection, i.e. they are acquired randomly and only those cells containing spacers with a correct PAM for Cas9 cleavage provide immunity and allow cell survival, we sequenced the PAMs of spacers acquired in the absence of phage infection ([Fig. 1c](#F1){ref-type="fig"} and [2c](#F2){ref-type="fig"}). Either Cas9^Sp^ or Cas9^St^ were produced in cells overexpressing Cas1^Sp^, Cas2^Sp^ and Csn2^Sp^. In this experiment, as explained above, spacers matching chromosomal or plasmid sequences will be acquired. The PCR products containing new spacers were cloned into a commercial vector from which they were sequenced ([Extended Data Table 1](#T1){ref-type="table"}). Expression of Cas9^Sp^ led to the incorporation of spacers matching protospacers with an NGG PAM sequence, whereas the expression of Cas9^St^ in the same cells shifted the composition of the PAM to NGGNG ([Fig. 2d](#F2){ref-type="fig"}). These results demonstrate that Cas9 specifies PAM sequences to ensure the acquisition of functional spacers during CRISPR adaptation.

Cas9 associates with other Cas proteins involved in spacer acquisition {#S4}
======================================================================

In type I CRISPR-Cas systems, Cas1 and Cas2 form a complex^[@R13]^ and the dsDNA nuclease activity of Cas1 has been implicated in the initial cleavage of the invading viral DNA to generate a new spacer^[@R26]^. The genetic analyses presented above suggest that in the type II *S. pyogenes* CRISPR-Cas system, the PAM-binding function of Cas9 observed *in vitro*^[@R7]^ could specify a PAM-adjacent site of cleavage for Cas1, or other members of the spacer acquisition machinery. This would guarantee that newly acquired spacers have the correct PAM needed for Cas9 activity later in this immune pathway. This hypothesis predicts an interaction between Cas9 and Cas1, Cas2 and/or Csn2. To test this we expressed the type II Cas operon in *E. coli*, using a histidyl tagged version of Cas9, and looked for other proteins that co-purify. We observed an abundant co-purifying protein with an apparent molecular weight close to 33 kDa, the expected size of Cas1 ([Extended Data Fig. 4a](#F7){ref-type="fig"}). Mass spectrometry confirmed the identity of both of these proteins as well as the presence of Cas2 and Csn2 co-purifying with Cas9 ([Extended Data Table 2](#T2){ref-type="table"}). This result suggested the formation of a Cas9-Cas1-Cas2-Csn2 complex and therefore we explored other purification strategies to unequivocally determine its existence. We were able to isolate a Cas9-Cas1-Cas2-Csn2 complex when the histidyl tag was added to Csn2 ([Fig. 3a and b](#F3){ref-type="fig"}). The identity of the purified proteins was confirmed by mass spectrometry ([Extended Data Table 3](#T3){ref-type="table"}). This demonstrates a biochemical link between the Cas9 nuclease and the other Cas proteins that function exclusively to acquire new spacers, supporting the role of Cas9 as a PAM specificity factor in the adaptation phase of CRISPR immunity.

The PAM binding motif of Cas9 is required for PAM selection {#S5}
===========================================================

Within this complex the PAM-binding domain of Cas9 would specify a functional spacer (one adjacent to a correct PAM) and the nuclease activity of Cas1 and/or Cas9 would cleave the invading DNA to extract the spacer sequence. To test this we performed adaptation studies in the absence of phage selection as described in [Extended Data Fig. 3](#F6){ref-type="fig"} but using different combinations of wild-type Cas1, Cas1^E220A^ (catalytically dead or dCas1^[@R26]^), wild-type Cas9, Cas9^D10A,H840A^ (catalytically dead or dCas9^[@R6]^) and Cas9^R1333Q,R1335Q^ (Cas9^PAM^, containing mutations in the PAM-binding motif that substantially reduces binding to target DNA sequences with NGG PAMs *in vitro*^[@R15]^). We observed that the nuclease activity of Cas1 is necessary for spacer acquisition ([Fig. 3c](#F3){ref-type="fig"}). In contrast, the nuclease activity and PAM-binding function of Cas9 are dispensable for this process. Next we determined the PAM of the acquired spacers in the presence of mutated Cas9 ([Fig. 3d](#F3){ref-type="fig"}). We found that whereas spacers acquired in the presence of dCas9 displayed correct PAMs, those acquired in the presence of Cas9^PAM^ matched DNA regions without a conserved flanking sequence, i.e. without a PAM sequence. The same result was obtained with St dCas9 ([Extended Data Fig. 5](#F8){ref-type="fig"}). Altogether these results indicate that Cas1 and Cas9 are part of a complex dedicated to spacer acquisition which requires Cas1 nuclease activity and Cas9 PAM-binding properties for the selection of new spacer sequences.

Discussion {#S6}
==========

The selection of new spacers with a correct PAM is fundamental for the survival of the infected host during CRISPR-Cas immunity. In the simplest scenario there is no active selection of PAM-flanked protospacers; any spacer sequence can be acquired but only those with the correct PAM allow Cas9 cleavage of the invader and survival. Bacteria that acquire spacers with ineffective flanking sequences are killed by the virus and as a consequence PAM-flanking spacers are enriched in the population. Here we show that even in the absence of phage selection, the type II CRISPR-Cas system acquires new spacers with correct PAMs, a result that rules out the possibility of random spacer selection with subsequent selection for functional spacers. How are PAM-flanked protospacers selected during type II CRISPR-Cas immunity? One possibility is that the proteins exclusively dedicated to spacer acquisition perform the PAM-selection function. The inability of cells over-expressing only *cas1, cas2* and *csn2* to expand the CRISPR array strongly suggest that none of the proteins encoded by these genes can recognize and select correct PAMs. Another possibility is that the known PAM recognition function of Cas9^[@R15],[@R27]^, essential for destroying the invading virus, could also be used during spacer acquisition to recognize PAM-flanking viral sequences. Experiments showing that the *cas9* allele, but not the *cas1-cas2-csn2* alleles, determine the PAM sequence of the newly acquired spacers, demonstrated that this scenario is likely correct. How does Cas9 select new spacers with the correct PAMs? Our experiments demonstrate that Cas9 forms a stable complex with Cas1, Cas2 and Csn2 that presumably participates in the selection of new spacers. The nuclease activity of Cas1, but not of Cas9, is required for spacer acquisition. The tracrRNA is also required, suggesting that the apo-Cas9 structure^[@R27]^, very different from holo-Cas9^[@R15]^, does not have the correct conformation to participate in spacer acquisition. The key residues involved in Cas9 PAM recognition are not required for spacer acquisition, but they are necessary for the incorporation of new spacers with the correct PAM sequence. This suggests that the reported non-specific DNA binding property of Cas9^[@R6],[@R7]^ is sufficient for spacer acquisition, but not for the selection of functional spacers. There are currently two models for the incorporation of new spacers into the CRISPR array, one where the future spacer sequence is cut from the invading viral DNA, the "cut and paste" model, and another where this sequence is copied from the viral genome, the "copy and paste" model^[@R28]^. In the context of the first model, our data suggests that, at a low frequency that may reflect the dynamics of spacer acquisition, Cas1 cleaves the invading genome to extract a new spacer sequence. However, on its own, Cas1 nuclease activity is non-specific^[@R26]^. Therefore we propose that through the formation of the Cas9-Cas1-Cas2-Csn2 complex, Cas9 binding to PAM-adjacent sequences provides specificity to Cas1 endonuclease activity. In the "copy and paste" model, Cas1 nuclease activity is most likely necessary for downstream events, such as the cleavage of the repeat sequence that precedes spacer insertion, and Cas9 is required to "mark" sequences adjacent to GG motifs to be copied into the CRISPR array. In any case, following yet unknown processing and integration events, the selected DNA becomes a new functional spacer, i.e. its matching protospacer will have the correct PAM to license Cas9 cleavage ([Extended Data Fig. 6](#F9){ref-type="fig"}). The molecular steps that take place after protospacer selection to incorporate it as a new spacer in the CRISPR array are still unknown. All genes of the type II-A CRISPR-Cas locus (*tracrRNA, cas9, cas1, cas2* and *csn2*) are required for spacer acquisition, therefore most likely all the members of the Cas9-Cas1-Cas2-Csn2 complex participate in the process. Future work will address this and other aspects of the mechanisms of spacer integration in different CRISPR-Cas systems. The present work reveals a new function for Cas9 in CRISPR immunity. This nuclease is fundamental for both the execution of immunity, participating in the surveillance and destruction of infectious target viruses, and the generation of immunological memory, selecting the viral sequences that allow adaptation and resistance to viral predators.

Methods {#S7}
=======

Bacterial strains and growth conditions {#S8}
---------------------------------------

Cultivation of *S. aureus* RN4220 (ref.^[@R18]^), was carried out in brain-heart infusion (BHI) or heart infusion (HI) media (BD) at 37 °C. Whenever applicable, media were supplemented with chloramphenicol at 10 µg/ml or erythromycin at 5 µg/ml to ensure pC194- (ref.^[@R16]^) and pE194-derived^[@R29]^ plasmid maintenance, respectively.

On-plate spacer acquisition assay {#S9}
---------------------------------

To detect individual adapted colonies on a plate, cells from overnight cultures were mixed with phage at MOI = 1 in top agar containing appropriate antibiotic and 5 mM CaCl~2~. The mixture was poured on BHI plates with antibiotic and incubated at 37°C overnight. Subsequently, colonies that survived phage infection were restreaked on fresh BHI plates in order to remove contaminating virus and dead cells. Plates were incubated at 37°C overnight. To check for spacer acquisition, individual colonies were resuspended in lysis buffer (250 mM KCl, 5 mM MgCl~2~ 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-100), treated with 50 ng/µl lysostaphin and incubated at 37°C for 5 minutes, then 98°C for 5 minutes. Following centrifugation (13,200 rpm), a sample of the supernatant was used as template for TopTaq PCR amplification with primers L400 and H050. The PCR reactions were analyzed on 2% agarose gels ([Fig. 1a](#F1){ref-type="fig"}).

In-liquid spacer acquisition assay {#S10}
----------------------------------

Overnight cultures launched from single colonies were diluted 1:1000 into a fresh 10-ml culture of BHI containing appropriate antibiotic and 5 mM CaCl~2~. When the cultures reached OD~600~ of 0.4, depending on the experiment, they were either infected with phage MOI = 1 ([Fig. 1b](#F1){ref-type="fig"}) or induced with 1 µg/ml anhydrotetracycline ([Fig. 1c](#F1){ref-type="fig"}). After 16 hours, plasmids carrying the CRISPR systems were extracted using a slightly modified QIAprep Spin Miniprep Kit protocol: the pelleted bacterial cells were resuspended in 250 µl buffer P1 containing 50 ng/µl lysostaphin and incubated at 37°C for 1 h, followed by the standard QIAprep protocol. 100 ng of plasmid DNA was used to amplify the CRISPR locus using Phusion DNA Polymerase (New England Biolabs) with the following primer mix: 3 parts JW8 and 1 part each of JW3, JW4 and JW5. The following cycling conditions were used: (1) 98 °C for 30 s; (2, 30 times) 98 °C for 10 s, 64 °C for 20 s, 72 °C for 10 s; (3) 72 °C for 5 min. The PCR reactions were analyzed on 2% agarose gels. To sequence individual spacers, the adapted bands were extracted, gel-purified and cloned via Zero Blunt TOPO PCR Cloning Kit (Invitrogen). CRISPR loci of individual clones were checked for expansion of the arrays by PCR using the primers listed above and sent for sequencing.

Phage Adsorption Assay {#S11}
----------------------

The phage adsorption assay was performed as described previously^[@R30]^ with minor modifications. Cells were grown in BHI and 10 mM CaCl~2~ to an OD~600~ of 0.4. The phage solution was prepared at 10^6^ pfu/ml and 100 µl of this was added to 900 µl of cells. The mixture was incubated for 10 min at 37°C to allow adsorption of the phage to the cellular membrane. The mixture was centrifuged for 1 min at 13,600 rpm and the number of phage particles left in the supernatant was determined by phage titer assay.

Phage titer assay {#S12}
-----------------

Serial dilutions of the phage stock were prepared in triplicate and spotted on fresh top agar lawns of RN4220 in HI agar supplemented with the appropriate antibiotic and 5 mM CaCl~2~. Plates were incubated at 37°C overnight (Fig. S2).

High-throughput sequencing {#S13}
--------------------------

Plasmid DNA was extracted from adapted cultures using the in-liquid spacer acquisition assay described above. 100 ng of plasmid DNA was used as template for Phusion PCR to amplify the CRISPR locus with primers H182 and H183. Following gel extraction and purification of the adapted bands, samples were subject to Illumina MiSeq Sequencing.

Plasmid construction {#S14}
--------------------

Construction of pWJ40 was described elsewhere^[@R17]^. For the construction of pC194- and pE194-derived plasmids, cloning was performed using chemically competent *S. aureus* cells, as described previously^[@R17]^. The Δ*cas1* (pRH059), Δ*cas2* (pRH061) and Δ*csn2* (pRH063) mutants were constructed by one-piece Gibson assembly^[@R31]^ from pWJ40 using the pairs of primers H016-H017, H018-H019, H020-H021, respectively. Plasmid pRH087 containing the wild type *cas* genes of *S. pyogenes* was obtained by inserting the first spacer of *S. pyogenes* (annealed primers H049 and H050 containing compatible BsaI overhangs) in pDB184 using BsaI cloning^[@R32]^. BsaI cloning was also used to construct pRH079 and pRH233 by inserting a φNM4γ4 targeting spacer (annealed primers H029 and H030) into pDB114 and pDB184, respectively. Plasmid pRH200 harbors the wild type CRISPR3 system from *S. thermophilus* LMD-9 amplified with H168 and H169 from genomic DNA. The fragment was inserted on pE194 via Gibson assembly using H166 and H167. pRH213 was constructed by replacing Cas9^Sp^ on pRH087 with Cas9^St^ from pRH200 using the primer pairs H232-H233 and H231-H234, respectively. pRH214 was constructed by replacing Cas9^St^ on pRH200 with Cas9^Sp^ from pRH087 using the primer pairs H227-H230 and H228-H229, respectively. pGG32 was created by reducing the CRISPR locus of pWJ40 to a single repeat. This was accomplished by \'round the horn PCR^[@R33]^ using primers oGG82 and oGG83, followed by blunt ligation. pRH228 was constructed by replacing Cas9^Sp^ on pGG32 with Cas9^St^ from pRH200 using the primer pairs H232-H233 and H231-H234, respectively. pRH223 was constructed as a three-piece Gibson assembly combining TetR+ptet from pKL55-iTet (primers B534 and B616), pE194 (primers B532 and B617) and the cas1, cas2, csn2 genes and the array from pGG32 (primers H176-H177). pRH231 was constructed from pGG32 by one piece Gibson assembly with primers H289-H290. pRH234 contains Cas1 E220A and was constructed via one-piece Gibson assembly from pRH223, respectively, using the primer pair H312-H313. pRH227 was constructed from pGG32 via two sequential single-piece Gibson assemblies: first, D10A was introduced with B337-B338 and second, H840A was introduced with B339-B340. pRH229 was constructed via one-piece Gibson assembly from pGG32 using the primer pair H276-H277. Plasmids pRH240, pRH241, pRH242, pRH243 and pRH244 were constructed by one-piece Gibson assembly with primers H237-H238 from pGG32, pRH228, pRH227, pRH229 and pRH231, respectively. pRH245 was constructed from pRH241 via two sequential single-piece Gibson assemblies: first, D10A was introduced with H336-H337 and second, H847A was introduced with H338-H339.

Isolation and sequencing of φNM4γ4 {#S15}
----------------------------------

For the initial isolation of φNM4, supernatants from overnight cultures of *S. aureus* Newman were filtered and used to infect soft agar lawns of TB4::φNM1,2 double lysogens^[@R19]^. A single plaque was picked and then plaque-purified in two additional rounds of infection using TB4 soft agar lawns, and subsequently used to lysogenize TB4. For the resultant lysogen, specific primers were used to verify the presence of φNM4 and the absence of φNM1,2 by colony PCR. High titer lysates of φNM4 (\~10^11^ p.f.u. ml^−1^) were then prepared from this lineage and used for infection of TB4/pGG9 soft agar lawns harboring spacer 2B^[@R17]^. An escaper plaque was picked and then plaque-purified in two additional rounds of infection using TB4/pGG9 soft agar lawns. The resultant φNM4γ4 phage exhibited a clear plaque phenotype and was used to prepare a high titer lysate from which DNA was purified, deep sequenced, and assembled as described previously^[@R17]^. The full sequence of the ϕNM4γ4 has been deposited on Genebank under accession number KP209285, and includes a 2784 bp deletion encompassing the C-terminal 80% of the φNM4 *cI*-like repressor gene.

Protein purification {#S16}
--------------------

### Cas9 {#S17}

pMJ806 (WT Cas9) plasmid was obtained from Addgene. Both the proteins were purified as described before^[@R6]^ with minor modifications as follows. The proteins were expressed in *E. coli* BL21 Rosetta 2(DE3) codon plus cells (EMD Millipore). Cultures (2 L) were grown at 37°C in Terrific Broth medium containing 50 µg/ml kanamycin and 34 µg/ml chloramphenicol until the *A*~600~ reached 0.6. The cultures were supplemented with 0.2 mM isopropyl-1-thio-β-d-galactopyranoside and incubation was continued for 16 h at 16 °C with constant shaking. The cells were harvested by centrifugation and the pellets stored at −80 °C. All subsequent steps were performed at 4 °C. Thawed bacteria were resuspended in 30 ml of buffer A (50 mM Tris--HCl pH 7.5, 500 mM NaCl, 200 mM Li~2~SO~4~, 10% sucrose, 15 mM Imidazole) supplemented with complete EDTA free protease inhibitor tablet (Roche). Triton X-100 and lysozyme were added to final concentrations of 0.1 % and 0.1 mg/ml, respectively. After 30 min, the lysate was sonicated to reduce viscosity. Insoluble material was removed by centrifugation for 1 hr at 15,000 rpm in a Beckman JA-3050 rotor. The soluble extract was bound in batch to mixed for 1 hr with 5 ml of Ni^2+^-Nitrilotriacetic acid-agarose resin (Qiagen) that had been pre-equilibrated with buffer A. The resin was recovered by centrifugation, and then washed extensively with buffer A. The bound protein was eluted step-wise with aliquots of IMAC buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 10% glycerol) containing increasing concentrations of imidazole. The 200 mM imidazole elutes containing the His~6~-MBP tagged *Cas9* polypeptide was pooled together. The His~6~-MBP affinity tag was removed by cleavage with TEV protease during overnight dialysis against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol. The tagless Cas9 protein was separated from the fusion tag by using a 5 ml SP Sepharose HiTrap column (GE Life Sciences). The protein was further purified by size exclusion chromatography using a Superdex 200 10/300 GL in 20 mM Tris HCl pH 7.5, 150 mM KCl, 1 mM TCEP, and 5% glycerol. The elution peak from the size exclusion was aliquoted, frozen and kept at −80 °C.

### Cas1 {#S18}

Plasmid pKW01 (Cas1-WT) was constructed by through amplification of pWJ40 as a template for polymerase chain reactions (PCRs) to clone Cas1 into pET28b-His~10~Smt3 using the primers PS192 and PS193. Full sequencing of cloned DNA fragment confirmed perfect matches to the original sequence. The pKW01 plasmid was transformed into *E. coli* BL21 (DE3) Rosetta 2 cells (EMD Millipore). Cultures were grown and protein was purified by Ni- affinity chromatography step, as mentioned before in Cas9 purification. The 200 mM imidazole elutes containing the His~10~-Smt3 tagged *Cas1* polypeptide was pooled together. The His~10~-Smt3 affinity tag was removed by cleavage with SUMO protease during overnight dialysis against 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 20 mM and 10% glycerol. The tagless Cas1 protein was separated from the fusion tag by using a second Ni-NTA affinity step. The protein was further purified by size exclusion chromatography using a Superdex 200 10/300 GL in 20 mM Tris HCl pH 7.5, 500 mM KCl, 1 mM TCEP, and 5% glycerol. The elution peak from the size exclusion was aliquoted, frozen and kept at −80 °C.

### Cas2 {#S19}

The sequence encoding Cas2 was PCR amplified with primers PS334 and PS335 from pWJ40 and inserted into a pET-His~6~ MBP TEV cloning vector (Addgene Plasmid \# 29656) using ligation independent cloning (LIC). Sequencing of the resultant plasmid (pPS059) confirmed the matches to the wild type sequence. The protein was expressed and purified following the same procedure as that for Cas9.

### Csn2 {#S20}

Plasmid pPS060 was constructed by through amplification of pWJ40 as a template for polymerase chain reactions (PCRs) to clone Csn2 into pET28b-His~10~Smt3 using the primers PS336 and PS337. Full sequencing of cloned DNA fragment confirmed perfect matches to the original sequence. Csn2 was expressed and purified following the same method as that of Cas1. Protein concentrations for all the purifications were determined by using the Bradford dye reagent with BSA as the standard. Previously Csn2 was shown to form a tetramer^[@R34]^.

Cas9-Cas1-Cas2-Csn2 complex {#S21}
---------------------------

pKW07 (His~10~-Cas9-Cas1-Cas2-Csn2) was constructed by amplification of pWJ40 with primers PS199/PS202 and pET16b (Novagen) with primers PS200/PS203, followed by Gibson assembly of the fragments. Plasmid pPS061 (His~10~Cas9-Cas1) was created by amplification of pWJ40 with primers PS202/PS355 and pET16b (Novagen) with primers PS203/PS354, followed by Gibson assembly of the fragments. Full sequencing of cloned DNA fragment was done to confirm perfect matches to the original sequence. The proteins were expressed in *E. coli* BL21 Rosetta 2(DE3) codon plus cells (EMD Millipore). Cultures were grown and protein was purified by Ni- affinity chromatography step, as mentioned before in Cas9 purification with minor modifications. The 200 mM imidazole eluates were dialyzed overnight against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol and subjected to mass spectrometry for the identification of the co-purifying proteins. pKW06 (Cas9-Cas1-Cas2-Csn2-His~6~) was constructed by amplification of pWJ40 with primers PS204/PS205 and pET23a (Novagen) with primers PS206/PS207, followed by Gibson assembly of the fragments. Full sequencing of cloned DNA fragment was done to confirm perfect matches to the original sequence. The proteins were expressed in *E. coli* BL21 Rosetta 2(DE3) codon plus cells (EMD Millipore). Cultures were grown and protein was purified by Ni- affinity chromatography step, as mentioned before in Cas9 purification with minor modifications. The 200 mM imidazole eluates were dialyzed overnight against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol. The proteins were further purified using a 5 ml SP Sepharose HiTrap column (GE Life Sciences), eluting with a linear gradient of 150 mM -- 1 M KCl.

Extended Data {#S22}
=============

![The *S. pyogenes* type II CRISPR-Cas system displays a strong bias for the acquisition of spacers matching viral protospacers with NGG PAMs\
**a**, Analysis of bacteriophage-insensitive mutant colonies using PCR and agarose gel electrophoresis, representative of five technical replicates. Bacteria and phage were mixed in top agar and incubated overnight. DNA was isolated from individual colonies resistant to phage infection and used as template for a PCR reaction with primers (arrows) H182 and H183 ([Extended Data Table 2](#T2){ref-type="table"}), which amplify the 5' end of the *S. pyogenes* CRISPR array. The size of the PCR band indicates the number of new spacers (shown at the top of the gel). Cells without additional spacers resist infection by a CRISPR-independent mechanisms, presumably envelope resistance. **b**, Analysis of acquired spacers during phage infection of a population of bacteria carrying the *S. pyogenes* type II CRISPR-Cas system. Liquid cultures of bacteria were infected with phage, surviving cells were collected at the end of the infection, DNA extracted and used as template for a PCR reaction as described above. Amplification products were separated by agarose gel electrophoresis and the DNA of the bands corresponding to products with additional spacers was extracted and sent for Mi-Seq next generation sequencing. Reads corresponding to newly acquired spacers were plotted according to their position in the phage ϕNM4γ4 genome (x-axis) and their abundance (y-axis). Each dot represents a unique spacer sequence; blue and red dots indicate a corresponding protospacer with an NGG or non-NGG PAM. Top and bottom plots indicate protospacers in the top and bottom strands of the ϕNM4γ4 DNA. The map as well as the different functions of the phage genes are indicated in between the plots. The raw data used to make this graph is in the Supplementary file. **c**, Weblogo showing the conservation of the 5' flanking sequences of 10,000 protospacers randomly selected from the experiment shown in b. Absolute conservation of the NGG PAM was observed.](nihms657330f4){#F4}

![**a**, Analysis of bacteriophage-resistant mutants that do not acquire a new spacer. Three colonies that survived phage infection in our in-plate adaptation assay (Fig. S1a) were subjected to phage adsorption assay. Briefly, surviving colonies as well as the wild-type *S. aureus* RN4220 control were grown in liquid and mixed with bacteriophage. After a brief incubation, cells were pelleted by centrifugation and the phages present in the supernatant (unable to bind and infect cells) were counted on a lawn of sensitive cells. The number of plaque-forming units (pfu) of a control experiment in the absence of host cells were used to determine the 100% free-phage, or 0% adsorption, value. No plaques were observed in the control experiment using wild-type cells and this value was used to set the 100% adsorption limit. The three CRISPR-independent, bacteriophage-resistant mutants displayed a marked defect in phage adsorption (about 50 %), indicating that most likely they carry envelope resistance mutations. Error bars: mean ± s.d. (*n*=3). **b**, *cas1, cas2* and *csn2* are not required for the execution of immunity using previously acquired spacers. Position within the phage ϕNM4γ4 genome of the type II CRISPR-Cas target used in this experiment. The protospacer sequence is in the bottom strand (shown in 3'--5' direction) and flanked by a TGG PAM (in green). **c**, Comparison of immunity provided by a type II CRISPR-Cas system programmed to target the sequence shown in panel a in the presence (wild-type, wt) or absence (Δ*cas1*,Δ*cas2*, Δ*csn2*) of *cas1, cas2* and *csn2*. Immunity is measured as the plaque forming units (pfu) of a φNM4γ4 phage lysate spotted on top agar lawns of *S. aureus* RN4220 cells containing no CRISPR system (−), a wild type *S. pyogenes* CRISPR-Cas type II system (wt, pRH233), or the same CRISPR-Cas systems with a deletion of cas1, cas2 and csn2 genes (Δ*cas1*,Δ*cas2*, Δ*csn2*, pRH079). Error bars: mean ± s.d. (*n*=3).](nihms657330f5){#F5}

![Generation of an experimental system for the overexpression of *cas1, cas2* and *csn2* and the detection of spacer acquisition in the absence of phage infection\
**a**, Plasmids used in the spacer acquisition experiments presented in [Fig. 1c](#F1){ref-type="fig"} and [Fig. 2c--d](#F2){ref-type="fig"}. pRH223 contains *cas1, cas2* and *csn2* from *S. pyogenes* under a tetracycline-inducible promoter. Cells containing this plasmid only acquired spacers when a second plasmid expressing *cas9* was introduced, pRH240 or pRH241, containing the *tracrRNA* gene, the leader and first repeat from the *S. pyogenes* type II CRISPR-Cas system as well as *cas9* from *S. pyogenes* (*cas9*^Sp^) or *S. thermophilus* (*cas9*^St^), respectively. The leader is a short, AT rich sequence immediately upstream of the first repeat that contains the promoter for the transcription of the CRISPR array. **b**, Highly sensitive PCR assay to enrich for amplification products of adapted CRISPR loci. Arrows indicate primer annealing position and direction. The forward primer (JW8) anneals on the leader. For the reverse primer, a cocktail of JW3, JW4 and JW5 was used. The three reverse primers anneal on the repeat and differ only in their 3'-end nucleotide that never matches the last nucleotide of the leader (red arrowhead). Because this nucleotide is critical for the annealing of the primers, loci that acquire spacers ending in A, C or T are preferentially amplified over unadapted loci. **c**, To quantify the sensibility of this technique, we mixed pGG32 (one repeat, unadapted) with pRH087 (repeat-spacer-repeat, adapted) in known ratios. The amplification of adapted plasmid was detected even when it represented 0.01% (10^4^) of the total plasmid template, representative of three technical replicates. This highly sensitive PCR assay is not required to detect acquisition during phage infection, as in this case adapted cells survive and are enriched within the population, making their detection much easier.](nihms657330f6){#F6}

![Purification of a Cas9-Cas1-Cas2-Csn2 complexes\
**a**, The *cas9-cas1-cas2-csn2* operon of *S. pyogenes* SF370 was cloned into the pET16b vector (generating pKW07) to add an N-terminal histidyl tag to Cas9 and express all proteins in *E. coli*. Purification was performed using Ni-NTA affinity chromatography. SDS-PAGE followed by Coomassie stain of the purified proteins revealed a co-purifying protein that was identified as Cas1 by mass spectrometry, representative of five technical replicates. Mass spectrometry identification of all the eluted proteins co-purifying with Cas9 is shown in [Extended Data Table 2](#T2){ref-type="table"}. **b**, The *cas9-cas1-cas2-csn2* operon of *S. pyogenes* SF370 was cloned into the pET23a vector (generating pKW06) to add an C-terminal histidyl tag to Csn2 and express all proteins in *E. coli*. Purification was performed using Ni-NTA affinity chromatography followed by ion exchange chromatography. The elution fractions that constituted the peak containing the complex ([Fig. 3a](#F3){ref-type="fig"}) were separated by SDS-PAGE and visualized by Coomassie staining, representative of three technical replicates.](nihms657330f7){#F7}

![dCas9^St^ can also support spacer acquisition\
A plasmid derived from pRH241 containing mutations in the active site of St Cas9 (D10A, H847A; dCas9^St^) was used to characterize spacer acquisition in the absence of phage infection. Upon over-expression of Cas1, Cas2 and Csn2 using anydrotetracycline (aTc), we were able to detect spacer acquisition. Sequencing of spacers and alignment of the protospacer flanking sequences demonstrated the selection of an NGGNG PAM. Image is representative of three technical replicates.](nihms657330f8){#F8}

![A model for the selection of PAM-flanking spacers by Cas9\
After injection of the phage DNA an adaptation complex formed by Cas9, Cas1, Cas2 and Csn2 uses the Cas9 PAM binding domain to specify functional protospacers, i.e., that are followed by the correct PAM. It is not known how the protospacer sequence is extracted from the viral DNA to become a spacer. In the "cut and paste" model, a nuclease, possibly Cas1, cuts the viral DNA to generate the spacer. In the "copy and paste" model the protospacer sequence is copied first. Once loaded with the selected protospacer sequence, this complex promotes the integration of this sequence into the CRISPR array, thus becoming a new spacer. Previous studies demonstrated that Cas1 dimerizes and interacts with Cas2 (ref.^[@R13]^); Csn2 has been determined to form a tetramer^[@R34]^.](nihms657330f9){#F9}

###### 

Sequences of the spacers analyzed in the sequence logos of [Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [Extended Data Fig. 5](#F8){ref-type="fig"}.

  Primer   Sequence
  -------- -----------------------------------------------------------------------------
  B337     gacgctatttgtgccgatagctaagcctattgagtatttc
  B338     gaaatactcaataggcttagctatcggcacaaatagcgtc
  B339     ggaaactttgtggaacaatggcatcgacatcataatcact
  B340     agtgattatgatgtcgatgccattgttccacaaagtttcc
  B532     ctttttccgtgatggtaactgttcatatttatcagagctcgtg
  B534     gagctctgataaatatgaacagttaccatcacggaaaaaggttatg
  B616     ttattttaattatgctctatcaa
  B617     gagtgatcgttaaatttatactgc
  H016     aggaggtgactgatgggagttcctgaatttaggatatgag
  H017     taaattcaggaactcccatcagtcacctcctagctgactc
  H018     ttaggatatgagtgaggcttttgatgaatcttaatttttc
  H019     ttcatcaaaagcctcactcatatcctaaattcaggaactc
  H020     tttgatgaatcttaataaaaatatggtataatactcttaa
  H021     ttataccatatttttattaagattcatcaaaagcctcccc
  H029     aaacaaaaatgttttaacacctattaacgtagtatg
  H030     aaaacatactacgttaataggtgttaaaacattttt
  H049     aaactgcgctggttgatttcttcttgcgctttttg
  H050     aaaacaaaaagcgcaagaagaaatcaaccagcgca
  H166     gaaatgtgagaagggacctctgataaatatgaacatgatgagtgatcg
  H167     ggactcttttatctctactcgtgctataattatactaattttataaggagg
  H168     agtataattatagcacgagtagagataaaagagtcctttggatgattcc
  H169     tgttcatatttatcagaggtcccttctcacatttcaatactagactc
  H176     ttgatagagcataattaaaataagatgccactcttatccatcaatcc
  H177     gcagtataaatttaacgatcactctaaaacctctccaactacctccc
  H182     nnnnncagcaaaattttttagacaaaaatagtc
  H183     nnnnncagaagaagaaatcaaccagcgc
  H227     taatggcaggttggagaacagtagtc
  H228     actactgttctccaacctgccattagtcacctcctagctgactc
  H229     agatttttcaaataaggagaaatgtttgaaatcatcaaactcattatggatttaatttaaactttttattttagg
  H230     acatttctccttatttgaaaaatctaaatttatagaaattattatacgc
  H231     aactttttattttaggaggcaaaaagcgtataataatttctataaatttagatttttcaaataagg
  H232     ttttgcctcctaaaataaaaagtttaaattaaatccataatgag
  H233     tgatggctggttggcgtac
  H234     caacagtacgccaaccagccatcaaccctctcctagtttggc
  H237     ggcgtactgatgaagattatttcttaataactaaaaatatgg
  H238     tttagttattaagaaataatcttcatcagtacgccaaccagcc
  H276     ttgatcaaaaacaatatacgtctacaaaagaag
  H277     tagacgtatattgtttttgatcaattgttgtatcaa
  H289     agcgcttgggagaaattcaaagaaatttatcagcc
  H290     tttctttgaatttctcccaagcgctttcaaaacgc
  H312     gatattatggcaccatttaggcctttagtgg
  H313     aaaggcctaaatggtgccataatatcgctagc
  H336     catactcaattggacttgctattggaacgaatagtgttgg
  H337     cgttccaatagcaagtccaattgagtatggcttagtc
  H338     gtaattatgatattgatgctattattcctcaagc
  H339     gaggaataatagcatcaatatcataattacttaatc
  JW3      aaaacagcatagctctaaaacg
  JW4      aaaacagcatagctctaaaaca
  JW5      aaaacagcatagctctaaaact
  JW8      ggcttttcaagactgaagtctag
  L400     cgaaattttttagacaaaaatagtc
  oGG82    aacattgccgatgataacttgag
  oGG83    gttttgggaccattcaaaacagcatagctctaaaacctcgtag
  PS192    CGCGGATCCATGGCTGGTTGGCGTACTGTTGTGG
  PS193    CGCCTCGAGTCATATCCTAAATTCAGGAACTCC
  PS199    CGAGCATATGACGACCTTCGATATGATCGGCAATGTTGAATGGAGACCATTC
  PS200    GAATGGTCTCCATTCAACATTGCCGATCATATCGAAGGTCGTCATATGCTCG
  PS202    CATCATCATCATCATCACAGCAGCGGCATGGATAAGAAATACTCAATAGG
  PS203    CCTATTGAGTATTTCTTATCCATGCCGCTGCTGTGATGATGATGATGATG
  PS204    CGACAAGCTTGCGGCCGCACTCGAGCTTTTTATTTTAGGAGGCAAAAATG
  PS205    GGATCTCAGTGGTGGTGGTGGTGGTGTACCATATTTTTAGTTATTAAGAAATAATC
  PS206    GATTATTTCTTAATAACTAAAAATATGGTACACCACCACCACCACCACTGAGATCC
  PS207    CATTTTTGCCTCCTAAAATAAAAAGCTCGAGTGCGGCCGCAAGCTTGTCG
  PS284    GCTAGCGATATTATGGcACCATTTAGGCCTTTAG
  PS285    CTAAAGGCCTAAATGGTgCCATAATATCGCTAGC
  PS334    TACTTCCAATCCAATGCAATGAGCTATCGCTATATG
  PS335    TTATCCACTTCCAATGTTATTATTAGCTTTCATCAAAGGC
  PS336    CGCGGATCCATGAACCTGAACTTTAGCCTGCTGG
  PS337    CGCCTCGAGTTACACCATATTTTTGGTAATCAG
  PS354    GTTCCTGAATTTAGGATATGAAACATTGCCGATCATATCGAAGG
  PS355    CCTTCGATATGATCGGCAATGTTTCATATCCTAAATTCAGGAAC

###### 

Mass spectrometry analysis of proteins purified through Ni-NTA shown in [Extended Data Fig. 4a](#F7){ref-type="fig"}.

  Figure     Spacer   Sequence PAM                            Target
  ---------- -------- --------------------------------------- ------------
  2b         1        gcaacaatgggaaccaagctatgttgatag aGGgt    phage
  1st logo   2        gagaacaaaaccatcctacccggtaataaa tGGta    phage
             3        aatagagatactttatctaacatgatacac gGGag    phage
             4        ccattttagatttcaaaagtttagtatctat aGGca   phage
             5        agtattggaatctgatgaatattcatctct cGGta    phage
             6        agaaaatttatacattgattattcaccaac aGGca    phage
             7        acatactccaaacaattgatggatttgtgt aGGtg    phage
             8        gctaagactgtgaagcataatactgctact aGGta    phage
             9        ttttaagctattcattttaaaaggtcatat gGGca    phage
             10       acttatgccgtttctatacttcactacagca tGGtc   phage
             11       atgaatggattgaagagaacacagacgaac aGGac    phage
             12       ccacaaatagaaatagagctagggagtttaa cGGta   phage
             13       attagttactccacaaatagaaatagagct aGGga    phage
             14       ggagtaactaatatctgaattgttatcagt tGGtt    phage
             15       tagttttttgagtatgcttactttttcttg tGGtt    phage
             16       tgaacgaattgtcagtatgtacagattaat aGGaa    phage
             17       cattacggacgtagtagaagcaattagaaa tGGaa    phage
             18       tggatatgacgaccaagatttagcgtttta aGGtg    phage
             19       cgacataacgctaatacatgtttgtcatag tGGtt    phage
             20       acaaacttaacaatagtggttttttcaaga gGGag    phage
                                                              
  2b         1        agagtacaatattgtcctcattggagacac tGGgG    phage
  2nd logo   2        tgtttgggaaaccgcagtagccatgattaa gGGtG    phage
             3        ctcatattcgttagttgcttttgtcataaa aGGtG    phage
             4        tttatgtctatatactcaaagtaatcatttt cGGaG   phage
             5        taatatcaacggtatgtgggtgtctggtga cGGtG    phage
             6        aataagtctaaaaaaccaacgtttaatgat tGGgG    phage
             7        gttgatattacgttcatagaacatacctga tGGtG    phage
             8        tcaatgtttggtacaagttggtcacagata tGGaG    phage
             9        ttagttactccacaaatagaaatagagcta gGGaG    phage
             10       caattgtttttcttggaaatcatatttata cGGcG    phage
             11       tatctaagtttgccaattattacattaaagc tGGtG   phage
             12       taggacatagagatgaaaaaacgactataa aGGtG    phage
             13       tgaagaaatgattcaagaaacacaaaagag tGGcG    phage
             14       tcggactgttagggtacgcgaagggcaaaa aGGaG    phage
             15       aatactttcttctaaaaaacctaagtcaac aGGaG    phage
             16       taatccaattacaacattaaaaattaatga cGGaG    phage
             17       acaatgttaagcaaccagcacattacacata cGGcG   phage
             18       ggattttaaaataaaagtaaatgttgatac tGGcG    phage
             19       caggcaatgttattttatcggattttaaaaa cGGcG   phage
             20       agaatctttattattagctgacttacaaga aGGtG    phage
             21       aaaaccccaatatcttttaaaaataaagtt aGGtG    phage
             22       tagggcaatgattgaagaatttgatgataa cGGaG    phage
                                                              
  2b         1        aaaggcaacatatttgaatcatcacatttat tGGaG   phage
  3rd logo   2        ttggaatggaattaaacaataaaactttta tGGaG    phage
             3        atattcatcagattccaatactacgttaat aGGtG    phage
             4        acaatttaaaaattagaaatgtaaatgtag aGGtG    phage
             5        cagaatgaactatgaaacaggggtccaact aGGtG    phage
             6        acataacatcaaaaccctttctgaagaaat tGGtG    phage
             7        taagttgtttgaaatgtacgagatggaagg aGGaG    phage
             8        atacgtgtaaagacatattagatcgagtca aGGaG    phage
             9        tgtgcaggagctacgttcaataaatgtgaa aGGaG    phage
             10       ttaagaaagttattgtcatcgagcttaaat tGGtG    phage
             11       acacacatactaaacctgaacgattaagga gGGgG    phage
             12       tttaccaacatccttagttgatagattttt aGGcG    phage
             13       gtttgaatacgttccgtttctgatacccagt aGGcG   phage
             14       aagttaaaaagaatttaaagtcaagaagta tGGgG    phage
             15       attctcagaagatagcgaagatgggagaaa aGGaG    phage
             16       tgagcgactgctgggtgtgcttcgaatagtt tGGcG   phage
             17       taatatatgctcatacttaattgaattgtc tGGtG    phage
             18       atcttcttttttaatacgtccatcaacaag cGGtG    phage
             19       cgatattggcggtgtgaataataactttaa aGGaG    phage
             20       caacgagctggcaacaacataagatgacag aGGcG    phage
                                                              
  2b         1        taaactactacgacttaagcaggtgccata tGGca    phage
  4th logo   2        gacaaatgctattcaacattcagttaaaga aGGta    phage
             3        acaattattaattgaacaagcgcaagctaa cGGct    phage
             4        cacatcaattagtaagacgccaaaagtaac aGGta    phage
             5        aaacgatgagtacacaaaatacaaaatcta cGGca    phage
             6        gtaataatatttttaataacctcaacatct tGGtc    phage
             7        tcatgaaaaagtgaattgctagtagtgtgt tGGtc    phage
             8        tacgctatcgcaaaagcagtcaaagctaaa gGGca    phage
             9        agggaatcttacagttattaaataactatt tGGat    phage
             10       aaaacgagcaaattaagtggtacgtagaca aGGgt    phage
             11       ctaaatgttgccatttcgttatctcctttc tGGta    phage
             12       actggatgacattgaacaaagcaccgaata tGGcc    phage
             13       taaatatttgataacaacattatacacgaa aGGag    phage
             14       cacatcaattagtaagacgccaaaagtaac aGGta    phage
             15       aaggtgatgacggcgaatggtacacaacata tGGtc   phage
             16       taacgacggtacttattccgtcgttgctac tGGtg    phage
             17       ataaataaaaaagttactactcacacacta aGGca    phage
             18       tctaggttcgaactcttctttaaatttaat aGGca    phage
             19       ctcatcaatatcattctgattggttatttt gGGat    phage
             20       tctctttgataaataactttatccacataa aGGtg    phage
             21       ttagacttttactttccattacttaaatca tGGtc    phage
             22       aatttgttcttgcgcttcaatagtgatagt aGGgt    phage
             23       ataagtctaaaaaaccaacgtttaatgatt gGGga    phage
                                                              
  2d         1        acatgttatgcatatcgtaagtgaagtcac aGGta    chromosome
  1st logo   2        agatcaaattgtaacaactaatcctattgc aGGta    chromosome
             3        gtttcagcaatatatctcttagtgcatcac cGGtt    chromosome
             4        tacaatgtaggctgctctacacctagcttc tGGgc    pRH223
             5        tttgattacaatggcacatgtacttatgcc tGGat    chromosome
             6        catttgtcttagcacatgaattaggtcatgc aGGtc   chromosome
             7        catgattgcacccattgttgcacctagtac aGGtt    chromosome
             8        taccaataacttaagggtaactagcctcgc cGGca    chromosome
             9        gagtatgtttgcgcgtgaagtggttgtgtc tGGat    pRH223
             10       agaatggttagatttatggcgtgatgtaac gGGca    chromosome
             11       ctgcttccatgataactggaccatcagcaac cGGat   chromosome
             12       gattgaagctacaatacctgatgttgctgc gGGaa    chromosome
             13       cgaaatacttggctaagcacgacgaggcct tGGtg    pRH223/240
             14       gctctacacctagcttctgggcgagtttac gGGtt    pRH223
             15       atatggaagttacattttttggaacgagtgc aGGtt   chromosome
             16       ttatgaagcgttacgtcaacaagattttcc aGGat    chromosome
             17       ttatcgaagtatacgagttcacagaagaac aGGct    chromosome
             18       ccagttcttgttgttttggtgctttagtca aGGtt    chromosome
             19       tggatgatcttgtctttcatgtgtacctgt tGGaa    chromosome
             20       caggatttagttttcctagcggtcatgcta tGGga    chromosome
                                                              
  2d         1        ttgactatcaaatgtctttttcaatgtttc gGGtG    chromosome
  2nd logo   2        atccgttctgcagaagagattgtttcttgc aGGcG    pRH223
             3        tgaacatttcgattatgtattaatgagtgc tGGtG    chromosome
             4        catctttaggacgaatgccagcacgttctgc tGGaG   chromosome
             5        caccatgttaaaaatacctccatcatcacc aGGaG    pRH223/240
             6        tcgtgagacagttcggtccctatccgtcgt gGGcG    chromosome
             7        tttgcgcagtcggcttaaaccagttttcgc tGGtG    pRH223
             8        aaagaagtcataagtaccatgacttgagtt tGGtG    chromosome
             9        ctaatttttcttcttcaacaccatctatggc tGGcG   chromosome
             10       ccaagtattcaaagttggaacgggtggtct aGGtG    chromosome
             11       atccgttctgcagaagagattgtttcttgc aGGcG    pRH223
             12       tttgcgcagtcggcttaaaccagttttcgc tGGtG    pRH223
             13       aacgcgtatacatagcaagcgttctcatgt tGGaG    chromosome
             14       agtttgggagtcaattatcggctttttaac tGGcG    chromosome
                                                              
  3d         1        tgacttctctgaagagccatctttttgcact tGGaa   chromosome
  1st logo   2        ggtcagatgcaattcgacatgtggacggac tGGtt    pRH223
             3        atcttttctagcttttctccaagcacagac aGGac    chromosome
             4        gttggtctaattgtttcaatagttccacct tGGtc    chromosome
             5        tgccggttggggtggctgagacggcaccct aGGaa    chromosome
             6        tgagtatgtttgcgcgtgaagtggttgtgtc tGGat   pRH223
             7        ttgagttagaaaacggtcgtaaacggatgc tGGct    pRH242
             8        agtttgggagtcaattatcggctttttaac tGGcg    chromosome
             9        aattaagaaatcttctaaccaactgattgc tGGaa    chromosome
             10       aacagaaagaataggaaggtatccgactgc tGGta    pRH223/240
             11       tggtattgtaggcgttattttaggtattcc gGGat    chromosome
             12       aaatctcagcaggacaagctggtacaggtgc tGGtt   chromosome
             13       ctcaagagatttggagcatccaatcaatgc aGGtc    pRH223
             14       ctaaggtggcaccacggtaacgcgtccttac aGGta   chromosome
             15       tgattaaacttaaaaatgtattacctagtgc aGGta   chromosome
             16       atttgagtcagctaggaggtgactgatggc tGGtt    pRH223
             17       ataagagaagatgctagacgtataagttcac tGGtc   chromosome
             18       acgttttatctgtatttgcgacaatcgttg gGGta    chromosome
             19       ataacatacgccgagttatcacataaaagc gGGaa    pRH223
             20       gcattttaaacaaaaaaagatagacagcac tGGca    pRH223
             21       aatcccagttagaacaaacgctaaaatggc gGGcc    chromosome
             22       taccaataacttaagggtaactagcctcgc cGGca    chromosome
                                                              
  3d         1        gaagtctagctgagacaaatagtgcgatta caaaa    pRH223/240
  2nd logo   2        agcatagctctaaaacctcgtagactattt ttgtc    pRH223/240
             3        aaattttttagacaaaaatagtctacgag gtttt     pRH223/240
             4        aagtcgaacttcataatcatcgctttcgg catat     chromosome
             5        ccaatttctacagacaatgcaagttggggt gtggg    chromosome
             6        gttatttctgaaatgcccgttacatcacgc cataa    pRH243
             7        tgtttgccctccaaatatgaaaacatggcc cggta    chromosome
             8        atgagatgaggcgataaaagaacgtcgcta aaacg    chromosome
             9        tactacttcaaggaattctatagaacctac tatat    chromosome
             10       gtaccacagtgccacatgttggcaattggc gagac    chromosome
             11       taaagctggtgaagcgattaacactgtacc aagta    chromosome
             12       atttcttcgttattagaaatataaaattgc gttgt    chromosome
             13       attttttatgattaagccatatggggttaa gcaag    pRH223/240
             14       aaagactgggatccaaaaaaatatggtggt tttga    pRH243
             15       attttcaaatgcataaaaactgtttctcaac gatat   chromosome
             16       ttttgtattggaatggcattttttgctatc aaggt    chromosome
             17       taaaacaggaccacttgtcatgtaagcttt aagtt    pRH223/240
             18       tgtatcttgtggtttcatctgtgctaacttt ggcag   chromosome
             19       agaggatgcagaacgtgcaatcttagctgc aagac    chromosome
             20       ttcaaacgagaataattatggcgttggttta ggtat   chromosome
             21       gcgaatacactcattaaaacaattgcatcc tgatt    chromosome
             22       tcttatcttgataataagggtaactattgc cgatg    chromosome
             23       caaataaaggtgcgttattaataacagtgc caggc    chromosome
             24       acaacagtacgccaaccagccatcagtcac ctcct    pRH223
                                                              
  S6         1        cagctaacaatgccatgattggtcggctga gGGaG    pRH223
             2        tggtaaatttacagaagatgctgaagatgc tGGtG    chromosome
             3        gagtcagctaggaggtgactgatggctggt tGGcG    pRH223
             4        caaataagtctagacatattagctcgttatc aGGtG   chromosome
             5        acgaccttgttgcaacatagcgccccactc tGGtG    chromosome
             6        acatgttatgcatatcgtaagtgaagtcac aGGtG    chromosome
             7        atccgttctgcagaagagattgtttcttgc aGGcG    pRH223
             8        agatgcttgttgtgttgtttgtgttgatgc cGGtG    chromosome
             9        atccgttctgcagaagagattgtttcttgc aGGcG    pRH223
             10       agtttgggagtcaattatcggctttttaac tGGcG    chromosome
             11       aaaaagttatctcgtagacattacactggc tGGgG    pRH245

###### 

Mass spectrometry analysis of protein bands from the purified Cas9-Cas1-Cas2-Csn2 complex shown in [Extended Data Fig. 4b](#F7){ref-type="fig"}.

  -------------------------------------------------------------------------------------------------------------
  Accession   Protein                                                        \%\        Unique\    Total\
                                                                             Coverage   Peptides   peak\
                                                                                                   area
  ----------- -------------------------------------------------------------- ---------- ---------- ------------
              Cas9                                                           83.26      170        9.7×10^10^

              Cas1                                                           91.35      40         1.9×10^10^

              Cas2                                                           84.07      13         1.9×10^9^

              Csn2                                                           91.82      18         2.9×10^9^

  P77398      Bifunctional polymyxin resistance protein ArnA (*arnA*)        85.76      43         8.2×10^8^

  P60422      50S ribosomal protein L2 (*rplB*)                              67.40      24         1.9×10^9^

  P17169      Glucosamine\--fructose-6-phosphate aminotransferase (*glmS*)   79.31      38         1.8×10^8^

  P0AA43      Ribosomal small subunit pseudouridine synthase A (*rsuA*)      85.71      17         8.9×10^8^

  P0A9K9      FKBP-type peptidyl-prolyl cis-trans isomerase (*slyD*)         68.88      7          3.7×10^9^

  P0ACJ8      Catabolite gene activator (*crp*)                              82.86      18         5.4×10^8^

  P45395      Arabinose 5-phosphate isomerase (*kdsD*)                       73.17      21         1.2×10^8^

  P0A6F5      60 kDa chaperonin (*groL*)                                     83.94      38         2.8×10^8^

  P0A9A9      Ferric uptake regulation protein (*fur*)                       78.38      8          1.2×10^9^

  P08622      Chaperone protein DnaJ (*dnaJ*)                                72.07      19         1.4×10^9^

  P00393      NADH dehydrogenase (*ndh*)                                     59.22      16         3.6×10^8^
  -------------------------------------------------------------------------------------------------------------

###### 

Oligonucleotides used in this study.

  Protein   \% Coverage   Unique Peptides   Total peak area
  --------- ------------- ----------------- -----------------
  Cas1      67.82         26                3.4×10^8^
  Cas2      90.27         13                1.2×10^9^
  Cas9      68.49         111               4.1×10^8^
  Csn2      82.27         19                4.1×10^8^
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![Cas9 is required for spacer acquisition\
**a**, Organization of the *S. pyogenes* type II CRISPR-Cas locus. Arrows indicate the annealing position of the primers used to check for the expansion of the CRISPR array. **b**, PCR-based analysis of liquid cultures to check for the acquisition of new spacer sequences in the presence or the absence of phage ϕNM4γ4 infection. Wild-type (WT) as well as different *cas* mutants were analyzed. Image is representative of three technical replicates. MOI; multiplicity of infection. **c**, Cultures over-expressing Cas1, Cas2 and Csn2 under the control of a tetracycline-inducible promoter were analyzed using PCR for spacer acquisition in the absence of phage infection. The strain was complemented with plasmids carrying either St or Sp Cas9 (see [Extended Data Fig. 3](#F6){ref-type="fig"}), in the last case with or without the *tracrRNA* gene (Δ*tracr*). Image is representative of three technical replicates. aTc; anhydrotetracycline.](nihms657330f1){#F1}

![Cas9 determines the PAM sequence of acquired spacers\
**a**, **c**, Genetic composition of the CRISPR-Cas loci tested for spacer during phage infection (**a**), or in the absence of infection, with the experimental set up shown in Fig. S4 (**c**). **b**, **d**, Sequence logos obtained after the alignment of the 3' flanking sequences of the protospacers matched by the newly acquired spacers in panels **a** and **c**, respectively. Numbers indicate the positions of the flanking nucleotides downstream from the spacer. n; number of sequences used in each alignment.](nihms657330f2){#F2}

![Cas9^Sp^ PAM recognition domain is required for the acquisition of spacers with an NGG PAM sequence\
**a**, Separation of the Cas9-Cas1-Cas2-Csn2 complex by ion exchange chromatography. **b**, SDS-PAGE of fraction 19 (peak) from the complex elution shown in panel a, representative of five technical replicates. The four proteins of the complex were individually purified and run alongside the purified fraction to identify each protein in the complex. **c**, Spacer acquisition was tested as in [Fig. 1c](#F1){ref-type="fig"} in the presence or absence of different Cas1 or Cas9 activities. Image is representative of eight technical replicates. dCas1, nuclease-dead Cas1 (E220A mutation); dCas9, nuclease-dead Cas9 (D10A, H840A mutations); Cas9^PAM^ lacks the PAM recognition function (R1333Q, R1335Q mutations). **d**, Sequence logos obtained after the alignment of the 3' flanking sequences of the protospacers matched by the newly acquired spacers in panel **c**. Numbers indicate the positions of the flanking nucleotides downstream from the spacer. n; number of sequences used in each alignment.](nihms657330f3){#F3}
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